ANNALS OF BIOMEDICAL ENGINEERING is a premier journal in the field of biomedical engineering, published by Springer. Established in 1972, this journal has become a vital resource for researchers, professionals, and students engaged in the rapidly evolving domain of biomedical technology. With a commendable impact factor and ranked in the 76th percentile among its peers as per Scopus, it exemplifies excellence in disseminating critical research findings. The journal covers a broad scope of topics related to the integration of engineering principles with medical and biological sciences, facilitating innovations that enhance healthcare outcomes. Although open access is not offered in this journal, it remains an essential platform for scholarly communication, contributing to the continuous advancement of knowledge in biomedical engineering. ANNALS OF BIOMEDICAL ENGINEERING is not only a bridge for academics to share groundbreaking research but also an influential guide for practical applications in medicine and health technologies, making it a fundamental publication for its readership.

Cellular and Molecular Bioengineering, published by SPRINGER, is a prominent journal dedicated to the exploration of interdisciplinary approaches in the fields of biochemistry, genetics, and molecular biology. With an ISSN of 1865-5025 and an E-ISSN of 1865-5033, this journal has been a pivotal resource since its inception in 2009, showcasing groundbreaking research that combines innovative modeling and simulation techniques with cellular and molecular applications. As a Q2 journal in both Biochemistry, Genetics and Molecular Biology (miscellaneous) and Modeling and Simulation categories, it ranks favorably in the Scopus metrics, placing 62nd out of 324 in Mathematics_ Modeling and Simulation, and 69th out of 221 in General Biochemistry, Genetics and Molecular Biology. The journal's commitment to quality research and its contribution to advancing academic dialogue make it essential for researchers, professionals, and students seeking to stay at the forefront of bioengineering innovation. While it currently does not offer open access, it continues to provide significant insights and empirical studies that can help shape future developments in the field, reinforcing its role as a key player in cellular and molecular bioengineering.

Welcome to the Journal of Orthopaedic Surgery and Research, a leading platform for disseminating innovative findings in the field of orthopaedic surgery and its related disciplines. Published by BMC, this esteemed journal has been an Open Access resource since 2006, ensuring that critical research is freely accessible to the global scientific community. Operating from the United Kingdom, the journal has achieved impressive rankings, placing in the Q2 category for Orthopedics and Sports Medicine and Q1 for Surgery in 2023. With its rigorous peer-review process and commitment to quality, it ranks 129th out of 551 in the Surgery category and 102nd out of 321 in Orthopedics and Sports Medicine on Scopus, reflecting its high impact and relevance. The journal covers a broad range of topics within the field, including clinical studies, surgical techniques, and rehabilitation, making it an essential resource for researchers, practitioners, and students seeking to advance their knowledge and contribute to the evolving landscape of orthopaedic medicine.

Biomedical Engineering Online, published by BMC, is an esteemed open-access journal in the United Kingdom that has been advancing the field of biomedical engineering since its inception in 2002. With a commitment to disseminating high-quality research, the journal encompasses a broad scope, including innovative studies in biomaterials, imaging technologies, and medical applications. Recognized within the Q2 quartile for various categories such as Biomaterials and Biomedical Engineering, it ranks favorably among its peers: Rank #58 out of 333 in Radiology, and Rank #15 out of 63 in Radiological and Ultrasound Technology in the Scopus database. These rankings, coupled with an open-access model, ensure that critical advancements in medical technology are accessible to researchers, health professionals, and students globally. As it continues through its converged years from 2002 to 2024, Biomedical Engineering Online remains an invaluable resource for anyone involved in the cutting-edge intersection of engineering and medicine.

Bioengineering-Basel, an esteemed journal published by MDPI, stands at the forefront of innovation in the field of bioengineering since its inception in 2014. With an E-ISSN of 2306-5354, this fully Open Access journal based in Switzerland provides a platform for researchers and professionals to disseminate cutting-edge findings across various aspects of bioengineering, including biomaterials, tissue engineering, and biopharmaceuticals. The journal has been recognized with a Q3 ranking in the 2023 Bioengineering category, reflecting its commitment to quality and relevance. By facilitating widespread accessibility to academic knowledge, Bioengineering-Basel aims to foster collaboration and stimulate thought leadership within the global research community, making it an indispensable resource for students, scholars, and industry practitioners alike.

Biomedical Engineering-Biomedizinische Technik, published by WALTER DE GRUYTER GMBH, serves as a pivotal platform for advancing knowledge in the field of biomedical engineering and medicine since its inception in 1956. With an ISSN of 0013-5585 and an E-ISSN of 1862-278X, this peer-reviewed journal offers accessible insights into innovative research and technological advancements that are reshaping healthcare practices and biomedical applications. Although rated in the Q3 category for both Biomedical Engineering and Miscellaneous Medicine in 2023, the journal's impact factor and growing reputation demonstrate its vital role in fostering academic dialogue and collaboration. The journal is based in Germany, while its scope encompasses a diverse range of topics, thus bridging the gap between engineering and medical disciplines. Researchers, professionals, and students alike are encouraged to engage with the content that not only highlights contemporary challenges but also presents groundbreaking solutions in biomedical technology.

IN VIVO is a prestigious academic journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of biochemistry, genetics, molecular biology, cancer research, and pharmacology. With its ISSN 0258-851X and E-ISSN 1791-7549, this journal has been a key contributor to innovative research since its inception in 1987, providing a crucial platform for the dissemination of significant findings in its scope. With an impressive impact reflected in its quartile rankings (Q2 in Biochemistry, Genetics and Molecular Biology and Medicine; Q3 in Cancer Research and Pharmacology), IN VIVO reaches a global audience comprising researchers, health professionals, and students. Although it operates on a subscription basis, the journal’s commitment to scientific excellence and rigorous peer review ensures that all published works maintain high quality and relevance. Notably positioned in Scopus ranks within the 36th to 59th percentiles across various categories, IN VIVO continues to be a vital resource for cutting-edge research and developments, solidifying its importance within the scientific community.

Journal of Biomedical Research, published by Nanjing Medical University in China, is a prominent platform for groundbreaking discoveries in the fields of Biochemistry, Genetics, and Molecular Biology, as well as Medicine. With an ISSN of 1674-8301 and an E-ISSN of 1876-4819, the journal offers a vital opportunity for researchers, professionals, and students to disseminate insightful research findings. Although not currently available as an open access journal, its inclusion in the second quartile of both Biochemistry and Medicine categories underscores its growing influence and commitment to high-quality scholarship, as evidenced by its historical compliance with Scopus rankings prior to 2009. By fostering an interdisciplinary approach, the Journal of Biomedical Research aims to bridge gaps in current biomedical understanding and encourages innovative research that can lead to significant contributions in improving health outcomes. Its editorial policies guarantee rigorous peer review, making it a trusted source of knowledge in the biomedical community.

Current Urology, published by Lippincott Williams & Wilkins, is a leading journal dedicated to advancing the fields of urology, oncology, and reproductive medicine. With an ISSN of 1661-7649 and E-ISSN of 1661-7657, this journal has established itself as a valuable resource for researchers, practitioners, and students alike, providing peer-reviewed articles that contribute to the ongoing discourse and development of these critical specialties. Operating out of the United States, Current Urology ranks in the third quartile for oncology, reproductive medicine, and urology, reflecting its importance in the medical community. The journal’s focus on innovative research and clinical practice allows it to bridge gaps between theoretical understanding and practical application, enhancing patient care and outcomes. Although currently not an open-access journal, it offers a wealth of insights and findings that underpin contemporary urological practices and research. In an evolving medical landscape, Current Urology remains an essential platform for disseminating knowledge and fostering collaboration among experts in the field.

Advanced Biology, published by WILEY-V C H VERLAG GMBH, serves as a premier platform where innovative research and scientific breakthroughs in the fields of biochemistry, genetics, and molecular biology converge. Established in 2021, this journal has rapidly ascended to prominence, securing Q1 rankings in its primary categories, including general biochemistry and biomedical engineering, and a solid Q2 ranking in biomaterials. With an ISSN of 2701-0198 and an emphasis on open access, Advanced Biology ensures that rigorous peer-reviewed research is accessible to a global audience, enhancing visibility and fostering collaboration among researchers, professionals, and students alike. By 2024, it aims to continually elevate scientific understanding and innovation, catering to the growing interdisciplinary nature of these critical fields. With Scopus rankings placing it amongst the top quartiles in its disciplines, Advanced Biology is poised to make significant contributions to the future of life sciences.